Skip to main content
CVKD
NASDAQ Life Sciences

Cadrenal 公布 CAD-1005 2期试验阳性数据及FDA审批路径，在4百万美元关键现金情况下

feedReported by GlobeNewswire
Sentiment info
Negative
Importance info
8
Price
$4.25
Mkt Cap
$9.937M
52W Low
$4.21
52W High
$19.03
Market data snapshot near publication time

summarizeSummary

Cadrenal Therapeutics 公布了2025年第四季度的财务报告，显示截至2025年12月31日，公司的现金及现金等价物余额为400万美元。同时，公司提供了CAD-1005计划用于HIT的企业更新，宣布了鼓舞人心的2期试验数据，并于2026年3月26日完成了End-of-Phase 2 FDA会议，该会议阐明了潜在的注册路径，以便进行计划中的3期关键试验。这一关键的现金状况，也在同日的8-K文件中被突出，表明公司迫切需要融资。虽然CAD-1005的积极临床和监管进展是公司首要资产的重大去风险事件，但不稳定的财务状况可能会严重阻碍这一有前途的药物的发展。投资者将密切关注公司的融资和战略替代方案的细节，以便为计划中的3期试验提供资金。

在该公告发布时，CVKD的交易价格为$4.25，交易所为NASDAQ，所属行业为Life Sciences，市值约为$993.7万。 52周交易区间为$4.21至$19.03。 这则新闻被评估为消极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed CVKD - Latest Insights

CVKD
Apr 29, 2026, 5:29 PM EDT
Filing Type: 424B3
Importance Score:
9
Cadrenal Therapeutics Finalizes Resale of 1.18M Shares, Enabling $5.35M Capital Infusion Amidst Going Concern
Sentiment: Negative
View Wiseek Article
CVKD
Apr 20, 2026, 7:55 PM EDT
Filing Type: S-3
Importance Score:
8
Cadrenal Therapeutics Files S-3 to Register 1.18M Shares for Resale, Enabling $5.35M in Future Warrant Exercise Proceeds Amidst Going Concern
Sentiment: Negative
View Wiseek Article
CVKD
Apr 01, 2026, 7:40 AM EDT
Filing Type: 8-K
Importance Score:
8
Cadrenal Therapeutics Secures $2.5M in Cash by Inducing Warrant Exercise, Issues New Warrants
Sentiment: Neutral
View Wiseek Article
CVKD
Apr 01, 2026, 7:30 AM EDT
Filing Type: 424B5
Importance Score:
9
Cadrenal Therapeutics Amends Warrants, Slashing Exercise Price by 73% to $4.50 Amidst Going Concern
Sentiment: Negative
View Wiseek Article
CVKD
Mar 31, 2026, 9:02 AM EDT
Filing Type: 10-K
Importance Score:
9
Cadrenal Therapeutics Faces Going Concern Warning Amid Critical Cash Shortage and Rising Losses
Sentiment: Negative
View Wiseek Article
CVKD
Mar 31, 2026, 8:55 AM EDT
Filing Type: 8-K
Importance Score:
8
Cadrenal Therapeutics Reports Q4/FY2025 Results, Advances CAD-1005 to Phase 3, Signals Urgent Need for Financing
Sentiment: Negative
View Wiseek Article
CVKD
Mar 31, 2026, 8:45 AM EDT
Source: GlobeNewswire
Importance Score:
8
Cadrenal Reports Positive CAD-1005 Phase 2 Data & FDA Path Amid Critical $4M Cash
Sentiment: Negative
View Wiseek Article
CVKD
Mar 12, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Cadrenal Therapeutics Highlights Preclinical Data for CAD-1005 in Obesity and Type 2 Diabetes
Sentiment: Positive
View Wiseek Article
CVKD
Feb 24, 2026, 8:35 AM EST
Filing Type: 8-K
Importance Score:
7
Cadrenal Therapeutics Reports Mixed Phase 2 Results for CAD-1005 in HIT; Advances to FDA End-of-Phase 2 Meeting
Sentiment: Neutral
View Wiseek Article
CVKD
Jan 02, 2026, 4:08 PM EST
Filing Type: 424B3
Importance Score:
8
Cadrenal Therapeutics Registers Over 428K Shares for Resale, Warning of Significant Dilution
Sentiment: Negative
View Wiseek Article